Highlights Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - OTC Markets Other stock markets 10:59:05 2024-06-10 am EDT			5-day change	1st Jan Change
2.2 ^USD	0.00%		-4.35%	-67.33%

May. 08	Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	CI
May. 06	Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	May. 07	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	May. 06	MT
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	Apr. 01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	Apr. 01	MT
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	Jan. 19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (EIGR) EIGER BIOPHARMACEUTICALS Posts Q3 Revenue $3.2M	Nov. 09	MT
Eiger to discontinue hepatitis drug study over safety concerns	23-09-12	RE
Eiger to discontinue hepatitis drug study	23-09-12	RE
Eiger BioPharmaceuticals, Inc. Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta	23-09-12	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Earnings Flash (EIGR) EIGER BIOPHARMACEUTICALS Posts Q2 Revenue $4.6M	23-08-14	MT
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Eiger Biopharmaceuticals to Focus on Metabolic Diseases with Avexitide	23-06-29	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments	23-04-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Highlights

Filters